       Document 0077
 DOCN  M9640077
 TI    CD4-imitating human antibodies in HIV infection and anti-idiotypic
       vaccination.
 DT    9604
 AU    Deckert PM; Ballmaier M; Lang S; Deicher H; Schedel I; Division of
       Clinical Immunology, Hannover Medical School,; Germany.
 SO    J Immunol. 1996 Jan 15;156(2):826-33. Unique Identifier : AIDSLINE
       MED/96133014
 AB    Anti-idiotypic vaccination against HIV infection aims at inducing an
       anti-gp120 immune response through anti-CD4 Abs mimicking epitopes of
       the gp120 molecule. The mAb IOT4a induces anti-gp120 Abs in rabbits.
       This study investigates the presence of human serum Abs cross-reacting
       with anti-CD4 mAbs and gp120 during HIV infection and after parenteral
       vaccination with IOT4a. Ten HIV-infected volunteers without
       immunodeficiency were inoculated s.c. with 0.6, 1.2, or 2.4 mg IOT4a.
       Six booster injections followed until day 35. Sera from study patients,
       80 HIV-positive, and 43 seronegative controls were examined by a panel
       of assays, including an ELISA using competition against biotinylated
       recombinant CD4, flow cytometry assaying inhibition of anti-CD4 mAbs and
       biotinylated gp120 binding to CD4-positive lymphocytes, and an IOT4a
       immunoblot. After vaccination, an increase in competitive binding
       activity, which was quantitative in ELISA and flow cytometry, was
       observed. In the ELISA, competition against biotin-CD4 was
       quantitatively quenched by preincubating sera with r-gp120 or anti-CD4
       mAbs such as IOT4a and Leu3a. Naive sera or sera from blood donors had
       no such effect in the assays employed, while 5/80 HIV sera showed
       binding qualities similar to vaccinees. These results suggest that 1)
       CD4 internal-image Abs emerge in a small proportion of HIV-positive
       individuals, and 2) parenteral vaccination with mAb IOT4a can induce a
       gp120 cross-reacting immune response that inhibits gp120 binding to CD4.
 DE    Adult  Animal  Antibodies, Anti-Idiotypic/BLOOD/IMMUNOLOGY/*THERAPEUTIC
       USE  Antibodies, Monoclonal/IMMUNOLOGY/*THERAPEUTIC USE  Antibody
       Specificity  Antigens, CD4/*IMMUNOLOGY  Comparative Study  Cross
       Reactions  Disease Progression  Enzyme-Linked Immunosorbent Assay
       Female  Human  HIV Envelope Protein gp120/*IMMUNOLOGY  HIV
       Infections/BLOOD/IMMUNOLOGY/*THERAPY  HIV-1/*IMMUNOLOGY  *Immunotherapy,
       Active  Male  Mice  Middle Age  *Molecular Mimicry  Rabbits  Recombinant
       Proteins/IMMUNOLOGY  Support, Non-U.S. Gov't  Vaccination  CLINICAL
       TRIAL  CLINICAL TRIAL, PHASE I  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

